Considering the success of the canine osteosarcoma and PII cervical cancer trials, I think proof of concept is pretty well proven. Now, as we know, nothing is infallible but the science failing is the least of my worries.
If it was, I think they would have removed the reference to it in the corp presentation. Why the process is taking this long, even taking into account the hold and protocol changes, is beyond me.
There isn't a worse service out there for investors who are looking to capitalize on the undervalued and overlooked opportunities from across the markets, these guys just keep delivering losing reports to their members.
As positive news emerges, it should get harder to take the stock down. The H&N data, if truly "remarkable" may play into that. Just my opinion.
Lest we forget, "Among 18 (69%) patients who received all 3 per-protocol doses, median OS exceeded 1 year (12.1 months) and 12-month survival was 55.6%."